Over the past 12‑18 months the Recombinant Factor C Assay market has accelerated through collaborations and product innovation. In Q2 2024, BioDetect partnered with Luminex to integrate its endotoxin‑free assay into the Luminex FLEXMAP 3D platform, expanding reach into clinical labs. Meanwhile, Merck KGaA completed the acquisition of EndoTech Solutions for $210 million, adding a patented recombinant Factor C kit to its diagnostics portfolio. In August 2024, Thermo Fisher Scientific launched the QuantifC™ assay, featuring a microfluidic cartridge that reduces run time to 15 minutes. Regulatory momentum grew as the EU updated its In‑Vitro Diagnostic Regulation (IVDR) Annex IV, granting a market‑access pathway for recombinant Factor C methods, prompting faster adoption across European manufacturers. Consumer trends show a shift toward endotoxin‑free bioprocessing, driving biotech firms to replace traditional LAL tests. Finally, Genomics Ventures announced a $45 million Series B round to scale manufacturing capacity in Singapore, targeting Asia‑Pacific demand. The February 2025 distribution agreement between EuroBio Labs and Pacific Diagnostics will extend assay availability across North America, matching rising endotoxin‑testing demand in pharma. These moves illustrate the evolving Recombinant Factor C Assay industry trends analysts track closely.
